Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Cisplatin

Peking University First HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Cisplatin cohort.

Asset / SponsorPhaseRating
Tucidinostat
Fudan University
Phase 2CCC
Vinorelbine
Peking University First Hospital
Phase 2CCC
Dapagliflozin
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Phase 2CCC

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
77 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →